This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ridker, P. M Search for Related Content PubMed PubMed Citation Articles by Ridker, P. M Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Pulmonary Embolism Genetics Home Reference Hazardous Substances DB WARFARIN Social Bookmarking                   What's this?

Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial

Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

PREVENT Investigators

Standard therapy for patients with deep venous thrombosis and pulmonary embolism typically includes anticoagulation for a 3-6-month period with full dose warfarin. However, patients following this regimen experience high rates of recurrent thrombosis, re-hospitalization and mortality in the years immediately following cessation of anticoagulation. This is true for patients at average risk of disease recurrence, and for patients at elevated risk due to the presence of inherited defects of anticoagulation such as factor V Leiden mutation. Unfortunately, no clinical regimen currently available has proven to have sufficient benefit to support long-term prophylaxis. In particular, full dose warfarin is associated with substantially increased risks of hemorrhage when used on a long term basis. In contrast, while targeted low-dose warfarin (INR 1.5-2.0) is safe for long-term therapy, the efficacy of this approach in the prevention of recurrent venous thromboembolic disease has remained untested.

The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial will evaluate the efficacy of prolonged treatment with low-dose warfarin in the secondary prevention of venous thromboembolism (VTE). Patients with a history of documented idiopathic venous thrombosis who have completed a standard course of anticoagulation therapy will be enrolled in a randomized, double-blind, placebo-controlled trial comparing usual care plus targeted low-dose warfarin to usual care plus placebo for a period of up to 4 years. Trial endpoints will include recurrent VTE, major bleeding episodes and all-cause mortality in the total patient population and separately in those patients with factor V Leiden.

The potential clinical impact of the PREVENT trial is broad since a positive finding would strongly support chronic low-intensity anticoagulation among patients with venous thrombosis who are at risk for recurrence following cessation of standard outpatient anticoagulation.

Key Words: factor V Leiden • prevention • pulmonary embolism • randomized clinical trial • venous thrombosis • warfarin

Vascular Medicine, Vol. 3, No. 1, 67-73 (1998)
DOI: 10.1177/1358836X9800300114


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. M Ridker, S. Z. Goldhaber, E. Danielson, Y. Rosenberg, C. S. Eby, S. R. Deitcher, M. Cushman, S. Moll, C. M. Kessler, C. G. Elliott, et al. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism N. Engl. J. Med., April 10, 2003; 348(15): 1425 - 1434. [Abstract] [Full Text] [PDF]

				M. H. Eckman, J. K. Erban, S. K. Singh, and G. S. Kao Screening for the Risk for Bleeding or Thrombosis Ann Intern Med, February 4, 2003; 138(3): W-15 - W-24. [Abstract] [Full Text] [PDF]

				H. V Joffe and S. Z Goldhaber Laboratory thrombophilias and venous thromboembolism Vascular Medicine, May 1, 2002; 7(2): 93 - 102. [Abstract] [PDF]

				A. R. Folsom, M. Cushman, M. Y. Tsai, N. Aleksic, S. R. Heckbert, L. L. Boland, A. W. Tsai, N. D. Yanez, and W. D. Rosamond A prospective study of venous thromboembolism in relation to factor V Leiden and related factors Blood, April 15, 2002; 99(8): 2720 - 2725. [Abstract] [Full Text] [PDF]

				M. H. Eckman, S. K. Singh, J. K. Erban, and G. Kao Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis Med Decis Making, April 1, 2002; 22(2): 108 - 124. [Abstract] [PDF]

				S.Z. Goldhaber Modern treatment of pulmonary embolism Eur. Respir. J., February 1, 2002; 19(35_suppl): 22S - 27s. [Abstract] [Full Text] [PDF]

				K. A. Bauer The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications Ann Intern Med, September 4, 2001; 135(5): 367 - 373. [Abstract] [Full Text] [PDF]

				D. G. Federman and R. S. Kirsner An Update on Hypercoagulable Disorders Arch Intern Med, April 23, 2001; 161(8): 1051 - 1056. [Abstract] [Full Text] [PDF]

				J. S. Miles, J. P. Miletich, S. Z. Goldhaber, C. H. Hennekens, and P. M. Ridker G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism J. Am. Coll. Cardiol., January 1, 2001; 37(1): 215 - 218. [Abstract] [Full Text] [PDF]

				R. J Beyth The recurrence rate of venous thromboembolism after a first or second episode of deep venous thrombosis was high Evid. Based Med., November 1, 2000; 5(6): 188 - 188. [Full Text]

				E. Heron, O. Lozinguez, M. Alhenc-Gelas, J. Emmerich, and J.-N. Fiessinger Hypercoagulable States in Primary Upper-Extremity Deep Vein Thrombosis Arch Intern Med, February 14, 2000; 160(3): 382 - 386. [Abstract] [Full Text] [PDF]